FIA
BMRN icon

FNY Investment Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

FNY Investment Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25
Closed -$2 – 470
2024
Q1 		$2 Hold
25
– – ﹤0.01% 576
2023
Q4 		$2K Buy
+25
New +$2.21K ﹤0.01% 391

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FNY Investment Advisers's BMRN Position: Q2 2025 in Review

FNY Investment Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 64 shares — an estimated $4K sold.

FNY Investment Advisers first reported a position in BMRN in Q1 2025 and held it in 1 quarter. The position peaked at $4K in Q1 2025. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • FNY Investment Advisers reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 64 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $4K.
  • FNY Investment Advisers first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • FNY Investment Advisers's BioMarin Pharmaceuticals position peaked at $4K in Q1 2025.
  • 582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on FNY Investment Advisers's 13F filing for Q2 2025, filed 30 Jul 2025.